Related Experiment Video
Updated: Sep 18, 2025

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
Published on: July 11, 2025
New Therapeutic Options for Fusariosis: A Patent Review (2008-2023)
Izadora Dillis Faccin1, Túlio Máximo Salomé1, Gleyce Hellen de Almeida de Souza1
1Health Sciences Research Laboratory, Universidade Federal of Grande Dourados, 79804-970 Dourados, Brazil.
Abstract:
Fusariosis is an infection caused by the fungus Fusarium spp., which is pathogenic to both plants and humans. The disease presents several clinical manifestations and epidemiological patterns. Current treatment relies on azoles and polyenes, but increasing antifungal resistance requires the exploration of new therapeutic options. This study reviewed patents related to the treatment of Fusariosis from the last 15 years (up to June 2023). The search identified 318 patents, categorized by identification code, publication date, type of application and mechanism of action, using the International Patent Classification and Cooperative Patent Classification systems. In addition, we conducted a bibliographic search in the PubMed database using the same criteria to identify the number of scientific articles. Of the 318 patents, 21 targeted Fusarium infections in humans. The years 2014 and 2018 stood out with three patents each, while the same period recorded an average of 58 published articles. The patents addressed mechanisms such as drug delivery, gene expression, immunotherapy, engineered drugs, and novel compounds. This research highlights the urgent need for continued innovation in therapeutic technologies to effectively treat Fusarium wilt.
Insights
Antifungal resistance necessitates new treatments for Fusariosis. Patent analysis reveals innovation in drug delivery, gene expression, and novel compounds for human Fusarium infections.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmaceutical Sciences
Background:
- Fusariosis, caused by *Fusarium* species, affects plants and humans.
- Current treatments (azoles, polyenes) face rising antifungal resistance.
- Novel therapeutic strategies are crucial for managing Fusariosis.
Purpose of the Study:
- To review patents for Fusariosis treatments over the last 15 years (up to June 2023).
- To identify trends in therapeutic approaches and mechanisms of action.
- To assess the landscape of innovation in combating *Fusarium* infections.
Main Methods:
- Systematic patent search using International Patent Classification and Cooperative Patent Classification.
- Bibliographic search in PubMed for scientific articles.
- Categorization of patents by identification code, publication date, application type, and mechanism.
Main Results:
- 318 patents related to Fusariosis treatment were identified.
- 21 patents specifically targeted human Fusarium infections.
- Key innovation areas include drug delivery, gene expression, immunotherapy, engineered drugs, and novel compounds.
- Peak patent activity observed in 2014 and 2018.
Conclusions:
- The patent landscape indicates active research into new Fusariosis therapies.
- Diverse mechanisms, including advanced drug delivery and immunotherapy, are being explored.
- Continued innovation is essential to address the challenge of antifungal resistance in Fusariosis treatment.
More Related Videos
Related Concept Videos
Fungal Phylum Microsporidia
Microorganisms in Medicine and Therapeutics
Combined Effects of Drugs: Synergism
Such synergistic combinations...

